炎症性肠病患者英夫利昔单抗与阿达木单抗治疗药物监测检测方法的比较
该研究比较了ELISA与HMSA两种方法检测炎症性肠病患者英夫利昔单抗和阿达木单抗浓度的差异。基于先前发现的差异,Prometheus Laboratories审查并校正了HMSA检测中英夫利昔单抗和阿达木单抗的向上漂移,并将校正后的浓度与原始ELISA值进行比较。
要点
- ELISA与HMSA检测抗TNF药物浓度存在差异
- HMSA检测英夫利昔单抗和阿达木单抗曾出现向上漂移
- 校正后的HMSA浓度与原始ELISA值进行了比较
核心结论
- HMSA检测英夫利昔单抗和阿达木单抗浓度存在向上漂移,校正后的浓度与原始ELISA值进行了比较。
研究设计与样本
- 比较ELISA与HMSA检测炎症性肠病患者英夫利昔单抗和阿达木单抗浓度的研究。
主要发现
- 该公司校正了错误值并向医生报告了修订后的药物浓度。
临床怎么用
- 临床决策依赖定义治疗药物浓度的阈值,需考虑检测方法不同可能导致阈值差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Comparison data regarding anti-tumor necrosis factor drug concentrations in inflammatory bowel disease (IBD) between the enzyme-linked immunosorbent assay (ELISA) and the homogenous mobility shift assay (HMSA) are scarce.1-3 As decisions in clinical practice depend on the thresholds that define a therapeutic drug concentration, it is important to determine if this varies based on the type of assay used for therapeutic drug monitoring.4 We recently showed a discrepancy between a commercially available ELISA and the HMSA for both infliximab and adalimumab concentrations in patients with IBD.5 Based on the results of the study, Prometheus Laboratories (San Diego, CA) initiated a comprehensive review of their HMSA assays and found that there was an upward drift for both infliximab (from December 2017 to May 2019) and adalimumab (from August 2017 to May 2019), including when our study was performed. Prometheus Laboratories corrected the errant values and reported the revised drug concentrations to physicians (Supplementary Methods). We aimed to compare the corrected infliximab and adalimumab concentrations with the original ELISA values.
引用
- Papamichael K, Clarke WT, Vande Casteele N, et al. Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020. PMID: 32147594. doi:10.1016/j.cgh.2020.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。